Início › Câncer de Pulmão de Não Pequenas Células › Pensilvânia

Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Pensilvânia

103 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Pensilvânia.

Cidades em Pensilvânia

Texto oficial do estudo (Inglês)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lehigh Valley Hospital-Cedar Crest, Allentown
UPMC Altoona, Altoona
UPMC-Heritage Valley Health System Beaver, Beaver
e mais 53

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

St. Lukes Hospital and Health Network ( Site 0186), Bethlehem

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06623422

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

UPMC-Heritage Valley Health System Beaver, Beaver
Carlisle Regional Cancer Center, Carlisle
UPMC Hillman Cancer Center Erie, Erie
e mais 17

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Abramson Cancer Center of the University of Pennsylvania, Philadelphia
University of Pittsburgh Medical Center, Pittsburgh
WellSpan York Cancer Center, York

RecrutandoFase 1/2

Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #104, Hershey
Exelixis Clinical Site #98, Philadelphia
Exelixis Clinical Site #32, Pittsburgh

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

AHN Cancer Institute - Allegheny General ( Site 9501), Pittsburgh

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06780085

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Perelman Center for Advanced Medicine ( Site 3205), Philadelphia

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07513376

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Bryn Mawr Hospital, Bryn Mawr
e mais 14

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06498635

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Lancaster General Hospital, Lancaster
Local Institution - 0028, Pittsburgh
WellSpan Oncology Research, York

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Alliance Cancer Specialists, Sellersville

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06765109

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Pittsburgh

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT05877599

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Spoknwrd Clinical Trials /ID# 273776, Easton

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Penn State Milton S. Hershey Medical Center, Hershey

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Alliance Cancer Specialists, PC, Bensalem
Consultants in Medical Oncology and Hematology, P.C., Broomall
Alliance Cancer Specialists, PC, Doylestown
e mais 5

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059), Hershey
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312137

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Alliance Cancer Specialists - Media, Media
Guthrie Medical Group, Sayre

RecrutandoFase 3

Idades de 18 a 100 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05920356

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Philadelphia
Research Site, Pittsburgh

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06218914

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Thomas Jefferson University Hospital, Philadelphia
Jefferson Health Northeast, Philadelphia
McGlinn Cancer Institute Reading Hospital, West Reading

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University of Pennsylvania, Philadelphia

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06667908

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Fountain Hill
Research Site, Kittanning
Research Site, Philadelphia

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
Jefferson Hospital Northeast, Philadelphia
AHN Allegheny General Hospital, Pittsburgh

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598

Pan-tumor MRD Study

Lancaster General Hospital (UPenn), Lancaster
Guthrie Foundation, Sayre
Cancer Care Associates of York (CCAY), York

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Bryn Mawr Hospital, Bryn Mawr
e mais 5

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT03191149

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
Local Institution - 0504, Philadelphia

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06561386

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Pittsburgh

RecrutandoFase 2

Idades de 18 a 95 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05061550

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Lankenau Medical Center, Paoli

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07028489

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Allegheny Health Network, Pittsburgh

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06128551

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Guthrie Robert Packer Hospital /ID# 270316, Sayre
Cancer Care Associates Of York /ID# 270971, York

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06568939

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Hospital of the University of Pennsylvania, Philadelphia
West Penn Allegheny Health, Pittsburgh

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07100080

An External Control Arm Study in Non-Small Cell Lung Cancer

Main Line Health, Wynnewood

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07174388

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0688, Easton
WellSpan Oncology Research, York

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06875310

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Hershey
Research Site, York

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Philadelphia
Clinical Study Site, Pittsburgh

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06767514

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

UPMC, Pittsburgh

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07020117

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04613596

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Allegheny Singer, Pittsburgh

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06303505

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

University of Pennsylvania, Philadelphia
WellSpan Medical Oncology & Hematology at York Cancer Center, York

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

St. Luke's University Health Network, Bethlehem
Allegheny Cancer Center, Pittsburgh
Reading Hospital - McGlinn Cancer Institute, West Reading

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06793215

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06345729

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.